

Michigan Pharmacy and Therapeutics Committee
Analgesics Workgroup
October 2008

The workgroup recommends to the full Committee the following:

Narcotics-Long Acting

- Move methadone to this class

 - Set up edits to require prior authorization if there has been no previous use of other narcotics within the six months before the request for methadone
 - Edit against use of concurrent other narcotics

- No changes to the current classification of the other drugs

Narcotics-Short and Intermediate Acting

- No further changes to the current classification of these drugs beyond reclassifying methadone

- Maintain the current editing on Actiq, regarding diagnoses for use and quantity

- Maintain edits on Oxycontin use

Non-Steroidal Anti-Inflammatory-COX II

- Remove prior authorization from Celebrex but place a quantity limit of 30 tablets maximum per prescription.

Central Nervous System Drug Workgroup
October 2008

The workgroup recommends the following to the full Committee:

Alzheimer's Dementia

- No change to the current classification of drug products

Anti-Anxiety General

- No change to the current classification of drug products

Drugs for ADHD

- Maintain clinical edit on this class

- Remove prior authorization from Vyvanse

 - Put a maximum quantity of 31 per prescription

- No changes to the classification of the other drug products

Sedative-Hypnotic Non Barbiturates

- Remove prior authorization from Rozerem

 - Set an edit to require prior authorization if beneficiary has had paid claims for benzodiazepines within the past six months

- No other changes to current classification of drug products, or use of prior authorization for more than three months' use of any drug(s) in the class